Table 2 Summary of results
From: Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis
Categories | Studies | Patients | Model | HR (95%CI) | Heterogeneity | |||||
|---|---|---|---|---|---|---|---|---|---|---|
NRT | Sur | value | z | P value | Chi2 | I2 | P value | |||
OS | ||||||||||
Neoadjuvant radiotherapy | 10 | 2081 | 5049 | Fixed | 0.81 (0.74–0.89) | 4.58 | < 0.001 | 14.01 | 36% | 0.12 |
Neoadjuvant radiotherapy_non-PSM | 6 | 454 | 2860 | Fixed | 0.78 (0.63–0.97) | 2.21 | 0.03 | 7.49 | 33% | 0.19 |
Neoadjuvant radiotherapy_PSM | 4 | 1627 | 2189 | Fixed | 0.82 (0.74–0.90) | 4.03 | < 0.001 | 6.38 | 53% | 0.09 |
RFS | ||||||||||
Neoadjuvant radiotherapy | 5 | 289 | 285 | Random | 0.58 (0.35–0.97) | 2.07 | 0.04 | 14.21 | 72% | 0.007 |
Sensitivity analysis | 4 | 156 | 152 | Fixed | 0.50 (0.36–0.71) | 3.91 | < 0.001 | 6.50 | 54% | 0.09 |
LR | ||||||||||
Neoadjuvant radiotherapy | 2 | 168 | 306 | Fixed | 0.70 (0.51–0.97) | 2.14 | 0.03 | 1.73 | 42% | 0.19 |